Prem P. Batchala

2 months ago | onlinelibrary.wiley.com | Robert Dreicer |Michael Devitt |Matthew McCord |Prem P. Batchala

1 Introduction In the United States, prostate cancer is the most common non-cutaneous malignancy in males [1]. Distant metastasis is present in 4%–25% of prostate cancer patients [2], but intracranial metastases are rare (0.6%–2.9%) and involve the meninges (66%) more commonly than the parenchyma (33%) [3]. Advanced prostate cancer (aPC) with small cell and neuroendocrine-transformed types are more frequently associated with intraparenchymal brain metastases (BMETS) [4].